Medical Journal of The Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
Thu, Jun 18, 2026
[Archive]
Volume 40, Issue 1 (1-2026)
Med J Islam Repub Iran 2026 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sadeghi R, Masoudi M R, Moqaddasi Amiri M. Effect of Comorbidities on In-hospital COVID-19 Mortality across Age Groups: A Retrospective Cohort Study in Iran. Med J Islam Repub Iran 2026; 40 (1) :444-449
URL: http://mjiri.iums.ac.ir/article-1-9892-en.html
URL: http://mjiri.iums.ac.ir/article-1-9892-en.html
Department of Public Health, Sirjan School of Medical Sciences, Sirjan, Iran , m.moqaddasi@sirums.ac.ir
Abstract: (19 Views)
Background: COVID-19 has emerged as one of the most significant healthcare challenges globally in recent years, affecting numerous individuals and resulting in fatalities, particularly among older adults and those with comorbidities. While the influence of comorbidities on mortality in COVID-19 patients has been explored in various studies, it has not been examined across different age groups. We evaluated the impact of comorbidities on COVID-19 mortality in three distinct age groups.
Methods: A total of 10,496 hospitalized patients with positive PCR results for COVID-19 in Sirjan city were included in the study. Underlying conditions, including diabetes, hypertension, cardiovascular disease, and chronic kidney disease, were documented alongside age, sex, and COVID-19 status. The chi-square test and logistic regression were employed to assess the impact of comorbidities on mortality across different age groups.
Results: A total of 2,038 (19.4%) patients had at least one comorbidity. The number of deaths from COVID-19 was 466 (4.4%), of which 197 had comorbidities. Hypertension and diabetes were the most prevalent underlying conditions among COVID-19 patients, occurring in 11.9% and 8.6% of cases, respectively. The presence of comorbidities was significantly associated with mortality in the overall population (OR=3.26, 95% CI: 2.69-3.94) as well as in individuals aged between 30 and 60 years (OR=2.63, 95% CI: 1.77-3.91) and those over 60 years (OR=1.58, 95% CI: 1.26-1.99). Furthermore, the number of comorbidities influenced the mortality rate among COVID-19 patients (OR=1.65 for two comorbidities and OR=1.97 for three or more comorbidities compared to patients with one comorbidity), although it did not vary across different age groups.
Conclusion: Comorbidities can influence the mortality rate associated with COVID-19 among individuals aged 30, particularly within the 30-60 year age group. While the presence of multiple comorbidities significantly elevates the risk of death in the overall population, this association was not found to be statistically significant when analyzed by age group.
Methods: A total of 10,496 hospitalized patients with positive PCR results for COVID-19 in Sirjan city were included in the study. Underlying conditions, including diabetes, hypertension, cardiovascular disease, and chronic kidney disease, were documented alongside age, sex, and COVID-19 status. The chi-square test and logistic regression were employed to assess the impact of comorbidities on mortality across different age groups.
Results: A total of 2,038 (19.4%) patients had at least one comorbidity. The number of deaths from COVID-19 was 466 (4.4%), of which 197 had comorbidities. Hypertension and diabetes were the most prevalent underlying conditions among COVID-19 patients, occurring in 11.9% and 8.6% of cases, respectively. The presence of comorbidities was significantly associated with mortality in the overall population (OR=3.26, 95% CI: 2.69-3.94) as well as in individuals aged between 30 and 60 years (OR=2.63, 95% CI: 1.77-3.91) and those over 60 years (OR=1.58, 95% CI: 1.26-1.99). Furthermore, the number of comorbidities influenced the mortality rate among COVID-19 patients (OR=1.65 for two comorbidities and OR=1.97 for three or more comorbidities compared to patients with one comorbidity), although it did not vary across different age groups.
Conclusion: Comorbidities can influence the mortality rate associated with COVID-19 among individuals aged 30, particularly within the 30-60 year age group. While the presence of multiple comorbidities significantly elevates the risk of death in the overall population, this association was not found to be statistically significant when analyzed by age group.
Policy Review: Original Research |
Subject:
Infectious Disease
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
